These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18508951)

  • 21. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
    Darwish M; Hellriegel ET
    Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers.
    Peterschmitt MJ; Burke A; Blankstein L; Smith SE; Puga AC; Kramer WG; Harris JA; Mathews D; Bonate PL
    J Clin Pharmacol; 2011 May; 51(5):695-705. PubMed ID: 20864621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
    Vollmer T; Blight AR; Henney HR
    Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
    Eder JP; Garcia-Carbonero R; Clark JW; Supko JG; Puchalski TA; Ryan DP; Deluca P; Wozniak A; Campbell A; Rothermel J; LoRusso P
    Invest New Drugs; 2004 Apr; 22(2):139-50. PubMed ID: 14739662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans.
    Almeida L; Soares-da-Silva P
    Drugs R D; 2003; 4(4):207-17. PubMed ID: 12848585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.
    Millward MJ; House C; Bowtell D; Webster L; Olver IN; Gore M; Copeman M; Lynch K; Yap A; Wang Y; Cohen PS; Zalcberg J
    Br J Cancer; 2006 Oct; 95(7):829-34. PubMed ID: 16969355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.
    Liu MY; Meng SN; Wu HZ; Wang S; Wei MJ
    Clin Ther; 2008 Apr; 30(4):641-53. PubMed ID: 18498913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
    Muehler A; Kohlhof H; Groeppel M; Vitt D
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):557-573. PubMed ID: 32361977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Midostaurin administration in two hemodialysis patients.
    Tollkuci E; Seddon A; Geswein L; Mulseh M
    J Oncol Pharm Pract; 2019 Jul; 25(5):1285-1288. PubMed ID: 30253726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
    Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
    Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT
    Nirogi R; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2021 May; 41(5):469-482. PubMed ID: 33788154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells.
    Huang YC; Chao DK; Clifford Chao KS; Chen YJ
    Toxicol In Vitro; 2009 Sep; 23(6):979-85. PubMed ID: 19573588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
    Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
    Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
    Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.